For the first time, cataract surgery has restored a falcon’s sight. A team of veterinarians and vision specialists from around the globe collaborated to restore sight to Banner, a four-year-old Lanner Falcon. The surgery was performed on Monday to restore Banner’s vision.
I’d taught her to come to the glove, and then she started missing. Soon she was coming to my knee or ankle.’
The bird lost her sight two years ago and hasn’t been able to fly or hunt since then. Banner’s owner Nancy Cowan says she first noticed something was wrong when training Banner. Cowan and her husband own a falconry in New Hampshire.
‘This is done in humans all the time, it’s just never been done in an animal. We didn’t just want to take up the cataract material. We wanted to replace it with a new lens.’
Dozens of people from Montreal to Ohio to Abu Dhabi were involved in the design of the artificial replacements for Banner’s cataract-stricken lenses.
The lenses were manufactured and donated by the Canadian company I-Med Pharma Inc. The operating theatre and expertise of the medical team were also donated. Banner now has to relearn how to relate to the world. Cowan and her husband are committed to helping Banner relearn how to relate to the world as a sighted bird.
‘If you have an animal, whether it’s a cat or dog or a bird, you feel responsible for its care and providing the best you can for it.’
I-MED Pharma Inc., a Montreal-based biotechnology company and Biocia Inc., a New Jersey-based biotechnology company announced today the Health Canada approval for their fourth generation preservative-free, multi-dose, viscoadaptive eye drop, I-Drop® PUR Gel for treating Ocular Surface Disorder (OSD) such as dry eye disease (DED). This product already received a CE mark earlier this year.
Viscoadaptive eye drops are topical solutions that exhibit both cohesive and dispersive behaviours depending on the shear energy in the solution. At low shear rates the solution exhibits cohesive behaviour (enhanced viscosity for lubrication, protection and prevention of evaporation of the tear film) and at higher shear rates it may exhibit dispersive behaviour (enhanced elasticity for optimal patient comfort and longer residence time requiring fewer applications during the day and/or night).
The I-Drop® commercial line of products is the only current commercially available viscoadaptive solution. The newly approved I-Drop® PUR Gel, 0.30% viscoadaptive hyaluronan, will be available in a simple to use, preservative-free multi-dose 10 mL bottle which dispenses sterile eye drops from the first to the last drop.
Ilan Hofmann, Ph.D., President of both I-MED and Biocia commented: “this latest approval will continue to strengthen I-MED’s commercial footprint in the Canadian OSD market which is projected to be growing >13% per year with state-of-the-art Products that are superior to others commonly marketed in Canada.
Wes Domareki, MBA, Chairman of the Board of Biocia Inc. commented: “I Drop® PUR Gel represents the culmination of years of successful research and development which is now being offered to suitable licensing partners on a worldwide basis moving forward”.
I-Drop® PUR Gel is scheduled to be launch in Q4 2013 in Canada with full distribution to follow in the rest of the world by early Q1 2014.
For further information contact:
Ilan Hofmann at Telephone number: (514) 685-8118, email: email@example.com
or Wes Domareki at: (908) 852-2311, e-mail: wesBIOCIA@aol.com